Q32 Bio (NASDAQ:QTTB) Given “Sell (D-)” Rating at Weiss Ratings

Weiss Ratings restated their sell (d-) rating on shares of Q32 Bio (NASDAQ:QTTB) in a research note released on Tuesday,Weiss Ratings reports.

Separately, Wall Street Zen raised shares of Q32 Bio from a “sell” rating to a “hold” rating in a report on Friday, October 3rd. Two analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $12.17.

Q32 Bio Stock Performance

Shares of NASDAQ:QTTB opened at $3.87 on Tuesday. The company’s 50-day moving average is $2.03 and its 200 day moving average is $1.88. The company has a market capitalization of $47.21 million, a P/E ratio of -0.90 and a beta of 0.11. Q32 Bio has a fifty-two week low of $1.35 and a fifty-two week high of $53.17.

Q32 Bio (NASDAQ:QTTB) last issued its quarterly earnings results on Wednesday, August 6th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.36. As a group, research analysts predict that Q32 Bio will post -12.32 earnings per share for the current year.

Institutional Investors Weigh In On Q32 Bio

Institutional investors and hedge funds have recently modified their holdings of the company. Goldman Sachs Group Inc. lifted its holdings in shares of Q32 Bio by 140.9% in the first quarter. Goldman Sachs Group Inc. now owns 44,373 shares of the company’s stock worth $73,000 after buying an additional 25,953 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Q32 Bio in the first quarter worth about $92,000. Jane Street Group LLC purchased a new stake in shares of Q32 Bio in the second quarter worth about $69,000. AQR Capital Management LLC purchased a new stake in shares of Q32 Bio in the first quarter worth about $68,000. Finally, Acadian Asset Management LLC purchased a new stake in shares of Q32 Bio in the first quarter worth about $50,000. 31.32% of the stock is owned by hedge funds and other institutional investors.

Q32 Bio Company Profile

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.